MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

首席执行官

Dr. Michael E. Castagna Pharm.D.

员工

403

国家

ISIN

US56400P7069

上市

0 Comments

分享你的想法

FAQ

Mannkind 今天的股价是多少？▼

MNKD 当前价格为 $6.1 USD，过去 24 小时上涨了 +1.5%。在图表上更密切关注 Mannkind 股价表现。

Mannkind 的股票代码是什么？▼

根据交易所不同，股票代码可能会有所不同。例如，在交易所，Mannkind 的股票以代码 MNKD 进行交易。

Mannkind 的股价在上涨吗？▼

MNKD 股票较上周上涨 +9.12%，本月上涨 +8.93%，过去一年 Mannkind 上涨 +9.52%。

Mannkind 的市值是多少？▼

今天 Mannkind 的市值为 1.87B

Mannkind 下一次财报日期是什么时候？▼

Mannkind 将于三月 03, 2026 发布下一次财报。

Mannkind 上一季度的财报怎么样？▼

MNKD 上季度财报为每股 0.03 USD，预估为 0.02 USD，带来 +60% 的意外。下季度预估财报为每股不适用 USD。

Mannkind 去年的营收是多少？▼

Mannkind 去年的营收为 571.01MUSD。

Mannkind 去年的净利润是多少？▼

MNKD 去年的净收益为 55.18MUSD。

Mannkind 有多少名员工？▼

截至二月 03, 2026，公司共有403名员工。

Mannkind 属于哪个行业？▼

Mannkind从事于Health Care行业。

Mannkind 何时完成拆股？▼

Mannkind 上次拆股发生在三月 03, 2017，比例为 1:5。

Mannkind 的总部在哪里？▼

Mannkind 的总部位于 US 的 Danbury。